As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Candel Therapeutics Inc. The largest reported stake is RTW Investments, LP's, at 8.8%. 5 filings are on record since January 21, 2026 (Schedule 13G, May 15, 2026).
Sell to companies like Candel Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 4,763,922 · Shared voting: 0 · Sole dispositive: 4,834,899 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-27
- · Reporting person: RTW Investments, LP · Sole voting: 0 · Shared voting: 6,422,018 · Sole dispositive: 0 · Shared dispositive: 6,422,018 · SCHEDULE 13G, 2026-05-15
- · Holder: BlackRock, Inc. · Percent: 4.2% · SCHEDULE 13G/A
- · Reporting person: Paul B Manning · Sole voting: 4,487,247 · Shared voting: 1,303,752 · Sole dispositive: 4,487,247 · Shared dispositive: 1,303,752 · SCHEDULE 13D/A, 2026-03-18
- · Holder: BlackRock, Inc. · Percent: 5.2% · SCHEDULE 13G
Candel Therapeutics Inc has 5 Schedule 13D or 13G filings on record since 2026-01-21. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| RTW Investments, LP | 8.8% | 6,422,018 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| 7.9% | 5,790,999 | SCHEDULE 13D/A, 2026-03-18 | 2024-12-16 | |
| BlackRock, Inc. | 6.6% | 4,834,899 | SCHEDULE 13G, 2026-07-27 | 2026-06-30 |
Holding shares or following this stake? See who's behind Candel Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Candel Therapeutics Inc and the records around it.
Candel Therapeutics Inc elsewhere on the record
- Leadership changes Sep 2026
- Who owns it
Companies that share a holder
- Paul B Manning also filed stake reports on 2 other companies: LIQUIDIA CORP (Aug 2026), Verrica Pharmaceuticals Inc. (Nov 2025)
- RTW Investments, LP also filed stake reports on 43 other companies: CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Candel Therapeutics Inc
Get an email when Candel Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Candel Therapeutics Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Candel Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Candel Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| RTW Investments, LP | 0 | 6,422,018 | 0 | 6,422,018 | SCHEDULE 13G, 2026-05-15 |
| Roderick Wong | 0 | 6,422,018 | 0 | 6,422,018 | SCHEDULE 13G, 2026-05-15 |
| Paul B Manning | 4,487,247 | 1,303,752 | 4,487,247 | 1,303,752 | SCHEDULE 13D/A, 2026-03-18 |
| The Paul B. Manning Revocable Trust dated May 10, 2000 | 2,763,527 | 0 | 2,763,527 | 0 | SCHEDULE 13D/A, 2026-03-18 |
| BKB Growth Investments, LLC | 0 | 1,303,752 | 0 | 1,303,752 | SCHEDULE 13D/A, 2026-03-18 |
| BlackRock, Inc. | 4,763,922 | 0 | 4,834,899 | 0 | SCHEDULE 13G, 2026-07-27 |
The latest filing identifies Candel Therapeutics Inc by CUSIP 137404109 and gives its principal executive office as 117 Kendrick St., Suite 450, Needham, MA 02494 (SCHEDULE 13G, 2026-07-27).
Source of funds (Item 3)
As of the date hereof, the Reporting Persons may be deemed to beneficially own an aggregate of 5,790,999 shares of Common Stock, consisting of (i) 1,681,000 shares of the Issuer's common stock held by Paul and Diane Manning, JTWROS, (ii) 2,763,527 shares of the Issuer's common stock held by the Trust, (iii) 1,303,752 shares of the Issuer's common stock held by BKB and (iv) 42,720 shares of common stock issuable upon the exercise of options within 60 days of February 26, 2026 held by Mr. Manning.Paul B Manning, SCHEDULE 13D/A, 2026-03-18
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-01-21 | BlackRock, Inc. | 5.2% | SCHEDULE 13G |
| 2026-03-18 | Paul B Manning | 7.9% | SCHEDULE 13D/A |
| 2026-04-27 | BlackRock, Inc. | 4.2% | SCHEDULE 13G/A |
| 2026-05-15 | RTW Investments, LP | 8.8% | SCHEDULE 13G |
| 2026-07-27 | BlackRock, Inc. | 6.6% | SCHEDULE 13G |
Questions about who owns Candel Therapeutics Inc
Who owns Candel Therapeutics Inc?
On this page, 3 holders' latest ownership filings report 5% or more of Candel Therapeutics Inc: RTW Investments, LP (8.8%, Schedule 13G, filed 2026-05-15), Paul B Manning (7.9%, Schedule 13D/A, filed 2026-03-18) and BlackRock, Inc. (6.6%, Schedule 13G, filed 2026-07-27).
Who are the largest shareholders of Candel Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Candel Therapeutics Inc on this page are RTW Investments, LP (8.8%), Paul B Manning (7.9%) and BlackRock, Inc. (6.6%).
When did RTW Investments, LP buy into Candel Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from RTW Investments, LP on this page is the Schedule 13G, filed 2026-05-15, reporting 8.8%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Candel Therapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 10, 2026 | Leadership change: Martine Zimmermann appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Candel Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.